Mikhail Blagosklonny is the professor of oncology at Rosewell Park Cancer Institute, Buffalo New York. The MD, Ph.D. appointment from April 2009 came about because of his vast experience in this field. The doctor has more than 170 research articles to his name including review and book chapters. He is also the founding editor of Cell cycle where he serves as the editor in chief.
Blagosklonny also serves as an associate editor of Cancer Biology & Therapy, cancer research, Autography, Cell Death & Differentiation, American Journal of Pathology, International Journal of Cancer as well as PLOS ONE. His interests in research range from molecular and cellular biology to the interesting clinical investigations which encompass cellular senescence, signal transduction, anticancer therapeutics that emphasize on both new and basic science strategies as well as cell cycle studies. Visit classroomvoices.org to read more about Mikhail.
The senior vice president at Rosewell attributes Mikhail as a preeminent researcher with a focus on areas such as cancer therapy and biology. It is believed that he is going to be a huge part of facilitating new anti-cancer strategies and cancer therapy methods for prevention. Everyone at Rosewell welcomes his recruitment to the organization with enthusiasm. There are shared ideas and approaches among them being the normal cell protection from chemo and radiotherapies, tissue-specific therapies, selective combinations of anticancer drugs as well as cancer prevention through slowing down of organismal aging.
Dr. Mikhail earned his Ph.D. in experimental medicine at the First Pavlov State Medical University of St. Petersburg as well as his MD in internal medicine. Mikhail Blagosklonny became an associate professor of medicine at New York Medical School in Valhalla in 2002 after which he was in charge of the Ordway Research Institute in Albany, New York as a senior scientist. This is a position he held until in 2009 when he was appointed the associate professor of Oncology at Rosewell Park Cancer Institute. His contributions on the subject of cancer treatment are well known in the field and beyond making him a success.